Current procedural terminology (CPT) codes serve as the universal language for medical billing, and selecting the correct code for hepatitis C screening is fundamental for both accurate reimbursement and appropriate patient care. The specific code assigned to this diagnostic process depends heavily on the clinical context, the methodology used, and the patient's risk profile. Understanding the nuances between these options ensures healthcare providers are properly compensated while maintaining compliance with evolving payer policies.
Understanding the CPT Code for Hepatitis C Antibody Testing
The most common scenario for hepatitis C screening involves the initial serologic test that detects antibodies to the virus. When a provider orders a test to see if a patient has been exposed to the hepatitis C virus (HCV), the standard CPT code is 86808. This code specifically identifies the "Antibody to hepatitis C virus (HCV) screening test, qualitative." It is the workhorse code for initial serologic screening and is reported once per patient, regardless of the number of samples sent to the lab, provided the methodology remains consistent.
Differentiating Between Screening and Confirmatory Testing
It is critical to distinguish between a screening test and a confirmatory test. The 86808 code is for the screening antibody test. If the initial screening returns a reactive or positive result, a confirmatory test is required to rule out false positives. This follow-up testing is not reported with 86808. Instead, providers must use CPT code 86810, which is designated for the "Reflex hepatitis C virus (HCV) RNA quantitative or qualitative." This code is billed only when the reflex RNA test is performed to confirm a positive antibody screen.
When to Use 86810 vs. 86808
Use 86808 for the initial order of HCV antibody screening.
Use 86810 only if the lab automatically reflexes a positive antibody test to an RNA assay, or if the provider specifically orders the RNA test to confirm a prior positive screen.
Billing both codes together for the same encounter is generally incorrect and may trigger payer denials. The RNA test is a definitive diagnostic tool, not a screening tool, and the reimbursement rate reflects the complexity of molecular analysis.
Risk-Based Testing and Clinical Scenarios
Hepatitis C screening recommendations have evolved to encourage broader testing. While traditional risk-based testing targeted populations with specific risk factors—such as intravenous drug users, recipients of pre-1992 blood products, or those with a history of unsafe medical procedures—current guidelines from the CDC now recommend one-time screening for all adults aged 18 to 79. Consequently, the 86808 code applies not only to high-risk patients but also to routine wellness visits where the provider decides to screen for HCV based on age or general health assessment.
Special Considerations: Pregnancy and Acute Presentations
In obstetric settings, hepatitis C screening is often part of the standard prenatal panel. The same CPT code 86808 applies when testing a pregnant patient for HCV antibodies. However, if a provider is evaluating a patient for acute hepatitis C infection—characterized by a recent onset of symptoms and likely exposure—the coding strategy may shift. While the screening code is often used initially, providers should be aware that if the clinical documentation specifically states "acute hepatitis C" and the provider is actively diagnosing an active infection, different E/M or consultation codes might be considered in conjunction with the lab tests, though 86808 remains the primary lab code for the serology.
